Scientific R&D
    Research Ability
News Activity
    News Center
        Createrna was invited to participate in the Chinese Pharmaceutical Innovation Investment Forum
        MY004567 tablets was clinically approved by FDS
        The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
        Dr. Jing Zhang, formerly Head of the Clinical Team at the FDA's Center for Drug Approval, serves as CMO of Createrna
        MY004567 tablets was approved by the FDA US. for clinical trials implied
        Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
        Createrna Receives Capital Injection from Well-known Investment Institutions
About Us
    About Createrna
        Company Introduction
        Development course
        Management Team
        Honor and Qualification
    Our Culture
    Contact Us
Join Us